Page last updated: 2024-12-07
4-aminophenyl alpha-d-mannopyranoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
p-aminophenyl alpha-D-mannoside : An alpha-D-mannoside having 4-aminophenyl as the anomeric substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 122647 |
| CHEMBL ID | 1173631 |
| CHEBI ID | 63030 |
| SCHEMBL ID | 291104 |
| MeSH ID | M0105208 |
Synonyms (35)
| Synonym |
|---|
| 4-aminophenyl |a-d-mannopyranoside |
| (2r,3s,4s,5s,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol |
| p-amph mannose |
| p-aminophenyl .alpha.-d-mannopyranoside |
| 34213-86-0 |
| .alpha.-d-mannopyranoside, 4-aminophenyl |
| 4-aminophenyl .alpha.-d-mannopyranoside |
| mannopyranoside, p-aminophenyl, .alpha.-d- |
| p-aminophenyl mannose |
| 4-aminophenyl .alpha.-d-mannoside |
| 4-aminophenyl alpha-d-mannopyranoside |
| chebi:63030 , |
| CHEMBL1173631 |
| (2r,3s,4s,5s,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol |
| alpha-d-man-oc6h4nh2 |
| 4-aminophenylmannoside |
| alpha-d-manp-oc6h4nh2 |
| 4-aminophenyl alpha-d-mannoside |
| p-aminophenyl alpha-d-mannopyranoside |
| p-aminophenyl alpha-d-mannoside |
| alpha-d-mannopyranoside, 4-aminophenyl |
| p-aminophenyl-alpha-d-mannopyranoside |
| 4-aminophenyl-alpha-d-mannoside |
| SCHEMBL291104 |
| 4-aminophenyl a-d-mannopyranoside |
| 4-aminophenyl i+/--d-mannopyranoside |
| DTXSID00187800 |
| AKOS027320453 |
| AS-63171 |
| 4-aminophenyl alpha-d-mannopyranoside, min. 98% |
| (2r,3s,4s,5s,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol |
| Q27132347 |
| 4-aminophenyl ?-d-mannopyranoside |
| 4-aminophenyl alpha -d-mannopyranoside |
| A875067 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| alpha-D-mannoside | Any mannoside in which the anomeric centre has alpha-configuration. |
| substituted aniline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1133344 | Insulin-like activity in albino CD rat fat cells assessed as stimulation of oxidation of [14C]glucose to 14CO2 at 100 ug/ml after 2 hrs by scintillation counting analysis relative to insulin | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Structure-activity relationships of aminoalkyl and -aryl glycosides having insulin-like activity. |
| AID492876 | Inhibition of Escherichia coli FimH-mediated hemagglutinination of guinea pig red blood cells assessed as drug level required for > 90% inhibition of hemagglutinination | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Structure-based drug design and optimization of mannoside bacterial FimH antagonists. |
| AID1133345 | Insulin-like activity in albino CD rat fat cells assessed as stimulation of oxidation of [14C]glucose to 14CO2 at 750 ug/ml after 2 hrs by scintillation counting analysis relative to insulin | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Structure-activity relationships of aminoalkyl and -aryl glycosides having insulin-like activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.73
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.73) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||